Pharmacology and Hypnotic Efficacy of Triazolam
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Triazolam is a new triazolobenzodiazepine drug that is indicated for the treatment of insomnia. The usual adult dosage is 0.25 to 0.5 mg; for geriatric patients a dose of 0.125 to 0.25 mg is recommended. Triazolam is readily absorbed and quickly eliminated with a half‐life of 2–5 hours, making it the shortest acting benzodiazepine available in the United States. Sleep laboratory and non‐laboratory clinical trials found triazolam 0.25 and 0.5 mg effective in inducing and maintaining sleep. It remained effective in laboratory studies of up to one month duration and non‐laboratory studies of up to six months duration when the drug was administered nightly. On discontinuation disturbed sleep for one or two nights was observed in some studies. Triazolam impairs performance for several hours after administration. However, unlike benzodiazepines with long‐acting metabolites, triazolam is relatively free of daytime residual effects, which is attributable to its short half‐life. Overall, triazolam is an effective and safe compound for the symptomatic treatment of insomnia complaints.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rebound Insomnia: A New Clinical Syndrome
Kales, A., Scharf, M. B., & Kales, J. D. (1978) · Science · doi:10.1126/science.684426 · Cited by 200
Anxiety caused by a short-life hypnotic.
Morgan, K., & Oswald, I. (1982) · BMJ · doi:10.1136/bmj.284.6320.942 · Cited by 137
Hypnotic Efficacy of Triazolam: Sleep Laboratory Evaluation of Intermediate‐Term Effectiveness
KALES, A., KALES, J. D., BIXLER, E. O., SCHARF, M. B., & RUSSEK, E. (1976) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1976.tb02414.x · Cited by 99
A comparison of the effects of flurazepam 30 mg and triazolam 0.5 mg on the sleep of insomniacs
Vogel, G. W., Barker, K., Gibbons, P., & Thurmond, A. (1976) · Psychopharmacology · doi:10.1007/bf00428706 · Cited by 72
Intermediate Use of Triazolam: A Sleep Laboratory Study
Roth, T., Kramer, M., & Lutz, T. (1976) · Journal of International Medical Research · doi:10.1177/030006057600400109 · Cited by 60
Self-citationChronic Use of Triazolam: The Effects on the Sleep Patterns of Insomniacs
Pegram, V., Hyde, P., & Linton, P. (1980) · Journal of International Medical Research · doi:10.1177/030006058000800308 · Cited by 29 · cited 3×
“25 T=CH T=CH T>CH NR NR NR (1980)43 (27) CH 500 T 0.”
Cited by
Sensitivity to triazolam in the elderly
Greenblatt, D. J., Harmatz, J. S., Shapiro, L., Engelhardt, N., Gouthro, T. A., & Shader, R. I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106133242403 · Cited by 258
Effect of Gradual Withdrawal on the Rebound Sleep Disorder after Discontinuation of Triazolam
Greenblatt, D. J., Harmatz, J. S., Zinny, M. A., & Shader, R. I. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709173171202 · Cited by 96
The natural history of tolerance to the benzodiazepines
Higgitt, A., Fonagy, P., & Lader, M. (1988) · Psychological Medicine. Monograph Supplement · doi:10.1017/s0264180100000412 · Cited by 37
Chronic benzodiazepine administration
Galpern, W. R., Miller, L. G., greenblatt, D. J., Szabo, G. K., Browne, T. R., & Shader, R. I. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90398-o · Cited by 17
Metadata
- Authors
- Roth, T., Roehrs, T. A., & Zorick, F. J.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 1983-05-06
- Volume
- 3
- Issue
- 3
- Pages
- 137-145
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W1542417561
- Cited by
- 48
- References
- 6
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacology and Hypnotic Efficacy of Triazolam. https://app.cochat.ai/papers/10.1002/j.1875-9114.1983.tb03237.x
- The paper
- Roth, T., Roehrs, T. A., & Zorick, F. J. (1983). Pharmacology and Hypnotic Efficacy of Triazolam. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/j.1875-9114.1983.tb03237.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.